What's in ProChon Biotech Ltd's pipeline?

ProChon Biotech Ltd has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with ProChon Biotech Ltd's portfolio?

Top competitors by shared drug class: Istituto Ortopedico Rizzoli, LG Life Sciences, Sanofi, Taipei Medical University, University of Sao Paulo General Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/prochon-biotech-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

ProChon Biotech Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ProChon Biotech Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Istituto Ortopedico Rizzoli · 1 shared drug class
LG Life Sciences · 1 shared drug class
Sanofi · 1 shared drug class
Taipei Medical University · 1 shared drug class
University of Sao Paulo General Hospital · 1 shared drug class
Wroclaw Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ProChon Biotech Ltd:

Cite this brief

Drug Landscape (2026). ProChon Biotech Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prochon-biotech-ltd. Accessed 2026-06-10.